%0 Journal Article %1 derwand2020supplementation %A Derwand, R. %A Scholz, M. %D 2020 %J Medical Hypotheses %K (h)cq covid-19 zinc %P 109815 %R https://doi.org/10.1016/j.mehy.2020.109815 %T Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? %U http://www.sciencedirect.com/science/article/pii/S0306987720306435 %V 142 %X Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.

@article{derwand2020supplementation, abstract = {Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.}, added-at = {2020-06-07T18:53:34.000+0200}, author = {Derwand, R. and Scholz, M.}, biburl = {https://www.bibsonomy.org/bibtex/29c5265c01e9a6b0d8eb7d2c6014758c7/fordham1}, description = {Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? - ScienceDirect}, doi = {https://doi.org/10.1016/j.mehy.2020.109815}, interhash = {6e4938fa579a81c78e3d1fb91a772856}, intrahash = {9c5265c01e9a6b0d8eb7d2c6014758c7}, issn = {0306-9877}, journal = {Medical Hypotheses}, keywords = {(h)cq covid-19 zinc}, pages = 109815, timestamp = {2020-06-07T18:53:34.000+0200}, title = {Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?}, url = {http://www.sciencedirect.com/science/article/pii/S0306987720306435}, volume = 142, year = 2020 }